CGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'
Patient-specific titanium implant designed for cranial and craniofacial reconstruction First Korean company to obtain FDA 510(k) clearance for a customized titanium implant in the U.S. market SEOUL, South Korea, April 24, 2026 /PRNewswire/ -- CGBIO...
CGBIO Showcases Minimally Invasive Spine Surgery Techniques in Thailand: "Smaller Incisions, Faster Recovery"
Korea–Thailand spine experts jointly lead advanced training on endoscopic spine surgery and lateral lumbar interbody fusion techniques Hands-on experience with Korean spine medical devices lays the foundation for advancing Asia's spine education hub...
CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry
- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial in spinal fusion - Positioned for global expansion in $750M spinal bone graft market SEOUL, South Korea, April 24, 2025 /PRNewswire/ -- CGBIO(CEO Hyun...
CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts
SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered with CGBIO to host the International Spine Endoscopy Training Course....